N. Hijiya Et Al. , "Efficacy and Safety of Nilotinib in Pediatric Patients with Philadelphia Chromosome-Positive (PH+) Chronic Myeloid Leukemia (CML): Results from A PHASE 2 Trial," PEDIATRIC BLOOD & CANCER , vol.64, 2017
Hijiya, N. Et Al. 2017. Efficacy and Safety of Nilotinib in Pediatric Patients with Philadelphia Chromosome-Positive (PH+) Chronic Myeloid Leukemia (CML): Results from A PHASE 2 Trial. PEDIATRIC BLOOD & CANCER , vol.64 .
Hijiya, N., Maschan, A., Rizzari, C., Shimada, H., Dufour, C., Goto, H., ... Kang, H. J.(2017). Efficacy and Safety of Nilotinib in Pediatric Patients with Philadelphia Chromosome-Positive (PH+) Chronic Myeloid Leukemia (CML): Results from A PHASE 2 Trial. PEDIATRIC BLOOD & CANCER , vol.64.
Hijiya, N. Et Al. "Efficacy and Safety of Nilotinib in Pediatric Patients with Philadelphia Chromosome-Positive (PH+) Chronic Myeloid Leukemia (CML): Results from A PHASE 2 Trial," PEDIATRIC BLOOD & CANCER , vol.64, 2017
Hijiya, N. Et Al. "Efficacy and Safety of Nilotinib in Pediatric Patients with Philadelphia Chromosome-Positive (PH+) Chronic Myeloid Leukemia (CML): Results from A PHASE 2 Trial." PEDIATRIC BLOOD & CANCER , vol.64, 2017
Hijiya, N. Et Al. (2017) . "Efficacy and Safety of Nilotinib in Pediatric Patients with Philadelphia Chromosome-Positive (PH+) Chronic Myeloid Leukemia (CML): Results from A PHASE 2 Trial." PEDIATRIC BLOOD & CANCER , vol.64.
@article{article, author={N. Hijiya Et Al. }, title={Efficacy and Safety of Nilotinib in Pediatric Patients with Philadelphia Chromosome-Positive (PH+) Chronic Myeloid Leukemia (CML): Results from A PHASE 2 Trial}, journal={PEDIATRIC BLOOD & CANCER}, year=2017}